Company news

BioMarin Pharmaceutical Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

June 23, 2025

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 15, 2025

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 11, 2025

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

April 30, 2025

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4: 30pm ET

April 16, 2025

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

April 1, 2025

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 20, 2025

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6: 50 AM PT / 9: 50 AM ET in Boston, MA

February 24, 2025

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

February 23, 2025

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

February 18, 2025

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4: 30pm ET

February 4, 2025

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

January 12, 2025

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9: 00 am PT / 12: 00 pm ET, in San Francisco, CA

January 5, 2025

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

November 15, 2024

BioMarin to Participate in Three Upcoming Investor Conferences

November 5, 2024

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

October 28, 2024

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4: 30pm ET

October 15, 2024

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

September 17, 2024

BioMarin to Host Investor Day Today at 10: 30 a.m. Eastern Time

September 3, 2024

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

September 3, 2024

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7: 45 AM PT / 10: 45 AM ET in New York, NY

August 28, 2024

BioMarin Announces New R&D and Business Development Leadership

August 20, 2024

BioMarin to Host 2024 Investor Day on September 4th in New York

August 18, 2024

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

August 4, 2024

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

August 4, 2024

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

July 23, 2024

BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4: 30pm ET

July 22, 2024

BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health

June 16, 2024

BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress

June 6, 2024

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10: 00am PT / 1: 00pm ET, in Las Vegas, NV

May 7, 2024

New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting

May 3, 2024

BioMarin Reports Record Financial Results for the First Quarter 2024

April 23, 2024

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4: 30pm ET

April 9, 2024

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 11, 2024

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

March 6, 2024

BioMarin Scheduled to Participate in March Investor Conferences

February 29, 2024

BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024

February 21, 2024

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4: 30pm ET

February 7, 2024

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

February 5, 2024

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10: 30 am PT / 1: 30 pm ET, in San Francisco, CA

January 2, 2024

BioMarin Announces Governance Enhancements and Value Creation Initiatives

December 19, 2023

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

November 27, 2023

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

October 31, 2023

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

October 31, 2023

U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

October 19, 2023

BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4: 30pm ET

October 16, 2023

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

September 20, 2023

BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia

September 14, 2023

BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York

September 10, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.